Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Medicinal Chemistry
Scientists at Amgen, Inc., Department of Medicinal Chemistry publish new data on medicinal chemistry
May 16th, 2008
Researchers detail in 'Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors,' new data in medicinal chemistry. "We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases," scientists in the United States report. "The inhibitory activity of this series was retained at the cellular level. Naphthamides 3, 20, and 22...
Source: Health Business Week (2008-05-16)
|
